|
Originally published In Press as doi:10.1074/jbc.M202117200 on May 10, 2002
J. Biol. Chem., Vol. 277, Issue 31, 27629-27635, August 2, 2002
Variant Forms of -Fetoprotein Transcripts Expressed in Human
Hematopoietic Progenitors
IMPLICATIONS FOR THEIR DEVELOPMENTAL POTENTIAL TOWARDS
ENDODERM*
Hiroshi
Kubota §,
Robert W.
Storms¶, and
Lola M.
Reid
From the Department of Cell and Molecular
Physiology and Program in Molecular Biology and Biotechnology,
University of North Carolina at Chapel Hill, School of Medicine, Chapel
Hill, North Carolina 27599-7038 and ¶ Medical Oncology and
Transplantation, Department of Medicine, Duke University Medical
Center, Durham, North Carolina 27710-2630
Received for publication, March 4, 2002, and in revised form, May 6, 2002
 |
ABSTRACT |
Hematopoietic stem cells have been
identified as multipotent cells that give rise to all adult
hematopoietic lineages. Although the hematopoietic lineage is
derived from the mesodermal germ layer in the embryo, recent data
suggest that bone marrow cells with an antigenic profile consistent
with that of hematopoietic stem cells can also differentiate to cell
types of the endodermal lineages, such as hepatocytes. However, the
molecular mechanisms associated with these events are entirely unknown.
For decades, -fetoprotein (AFP) has been used as a differentiation
marker for endodermal cells, because it was thought that the
transcription of AFP mRNA is tightly regulated in a developmental
and tissue-specific process. In this report we describe two new variant
forms of AFP transcripts in human hematopoietic progenitors that are
not expressed in mature cells. The variant AFP (vAFP) cDNA
sequences isolated from a multipotent hematopoietic cell line, K562,
revealed that the vAFP differed from the authentic transcript,
consisting of 15 exons, by replacing exon 1 of AFP with one or two
exons located in the 5'-untranslated region of the
AFP gene. In addition to the K562 cell line, vAFP
transcripts were detected in normal bone marrow, thymus, and brain but
were not detected in normal spleen, intestine, liver, or the
hepatocellular carcinoma cell line, HepG2. This suggests expression in
normal hematopoietic progenitors. This hypothesis was confirmed by the
finding that CD34+Lin hematopoietic
progenitor cells purified from cord blood by flow cytometric sorting
also expressed the variant transcripts. These results suggest that some
hematopoietic progenitors are in a state that permits them to express
certain types of transcripts that have been considered unique to endoderm.
 |
INTRODUCTION |
Stem cells, pluripotent cells capable of extensive growth without
losing their multipotentiality, are becoming the centerpieces of new
strategies for cell therapies, gene therapies, and tissue engineering,
all contributing to a new era in medicine (1-3). The molecular
machinery of self-renewal and differentiation is one of most intriguing
subjects of stem cell biology. Analyses of gene expression patterns
using subtracted cDNA library or cDNA microarray techniques
have revealed several candidates of new or known transcripts that are
expressed exclusively in stem cell populations, but not in terminally
differentiated cells (4, 5). These studies provide enormous information
facilitating the development of approaches for understanding stem
cells. However, the applied techniques have an intrinsic weakness in
that they cannot detect the stem/progenitor cell-specific isoforms of
transcripts having relatively long domains in common between the
isoforms. Therefore, an alternative strategy is to analyze individual
genes with expression that is regulated in developmentally specific ways in particular cell lineages.
Cell differentiation in the developing embryo is regulated by extrinsic
inductive signals and an intrinsic programmed genetic code.
Differentiation into the three germ layers (ectoderm, endoderm, and
mesoderm) from primitive ectoderm (epiblast) is a crucial step during
development and thought to be an irreversible process. This leads to
the development of unique cell types from each germ layer,
e.g. epidermal or neuronal cells from ectoderm; epithelial cells in internal organs or digestive tract from endoderm; and hematopoietic and mesenchymal cells from mesoderm. Recent studies (6,
7) of cell transplantation, however, suggest that somatic stem or
progenitor cells from adult tissues are able to generate cells with
fates different from those normally associated with the germ layer that
gave rise to the stem cells. A typical example of so-called
"transdifferentiation" is that of murine bone marrow-derived ckithighThylowLin Sca-1+
cells giving rise to mature hepatocytes (8). This antigenic profile is
used to define hematopoietic stem cells. Although reports about these
examples of possible transdifferentiation in mammals are accumulating
(9), it remains to be determined whether the studies observed
transdifferentiation or identified more primitive progenitors than
hematopoietic stem cells in bone marrow. In addition, recent reports
proposed that spontaneous cell fusion between transplanted donor
progenitors and recipient cells might cause misinterpretation in
previous studies reported as possible transdifferentiation (10, 11). In
any event, biochemical analyses are necessary for understanding
multipotency of the cells not only in those experimental setting but in
normal physiological environment.
Adult liver parenchymal cells consist of hepatocytes and biliary
epithelial cells. They are derived from common precursors, hepatoblasts, during embryonic development (12). The bipotent progenitors originate from multipotent endodermal cells in the foregut
by inductive signals from the septum transversum surrounding the
outgrowth of the endoderm (13). Although it is not known whether the
bone marrow-derived cells can differentiate into hepatoblasts or can
convert directly to hepatocytes, the cells possessing potential for
hepatic differentiation should express some early endodermal markers
before full differentiation into hepatocytes.
One such marker is -fetoprotein
(AFP),1 which is a major
serum protein produced primarily by visceral endoderm of the yolk sac
and by hepatoblasts as well as more differentiated fetal hepatic cells
(14, 15). AFP is one of the earliest markers for endodermal differentiation; the transcriptional expression starts with the appearance of visceral endoderm in the early embryo and is regulated tightly by developmental and tissue-specific cues (14-16). Therefore, in most studies that assess endodermal differentiation of human embryonic stem cells or embryonic germ cells, the expression of AFP
transcripts or the products have been used as a marker of endoderm
(17-19).
In this study, we have identified two variant forms of human AFP
transcripts from a multipotent hematopoietic cell line, K562. The
cDNA sequences revealed that the differences in the variant AFP
(vAFP) mRNAs from that of the authentic transcript, which consists
of 15 exons, is the presence of one or two unique exons, named exon A
and exon B, replacing exon 1 of AFP. The variant forms were
detected in normal CD34+Lin hematopoietic
progenitor cells but not in mature blood cells. The expression of the
variant AFP transcripts suggests that hematopoietic progenitors are in
a state that permits them to express certain types of transcripts that
have been considered unique to the endoderm.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
The human hepatoblastoma cell line,
HepG2, was maintained in Eagle's MEM supplemented with 1 mM sodium pyruvate, 2 mM
L-glutamine, 50 units/ml penicillin, 50 µg/ml
streptomycin, 0.1 mM MEM non-essential amino acids
solution, 5 µg/ml insulin, and 10% fetal bovine serum. The human
erythroleukemia cell line, K562 was maintained in DMEM/F12 supplemented
with 2 mM L-glutamine, 50 units/ml penicillin,
50 µg/ml streptomycin, 5 × 10 5 M
2-mercaptoethanol and 10% fetal bovine serum. HepG2 and K562 were
obtained from the Tissue Culture Core Facility of the Cancer Center at
the University of North Carolina at Chapel Hill. Normal human fetal
lung fibroblasts, MRC5 (American Type Culture Collection), were
cultured in the same supplemented DMEM/F12 in the presence of 10%
horse serum (Sigma) and 1 ng/ml of bovine FGF-2 (Collaborative Biomedical Research).
Polymerase Chain Reaction--
The primer sequences used for PCR
are shown in Table I. For reverse transcriptase-PCR (RT-PCR), total
RNAs were extracted from various cell lines and subjected to cDNA
synthesis. Briefly, cDNAs were synthesized from 10 µg of total
RNAs by oligo(dT) priming and AMV reverse transcriptase (Seikagaku) in
a reaction volume of 20 µl at 42 °C. PCR was performed in a total
volume of 50 µl consisting of 1 µM each primer, 200 µM each dNTP, 50 mM KCl, 1.5 mM
MgCl2, 10 mM TrisHCl, pH 8.3, and 1.25 units of
Amplitaq polymerase gold (PerkinElmer Life Sciences) with synthesized
cDNA. Samples were heated to 94 °C for 3 min followed by
amplification for 30 cycles for AFP or 35 cycles for vAFP of 2 min at
94 °C, 2 min 62 °C, and 3 min at 72 °C. After the last cycle,
a final extension step was done at 72 °C for 6 min. Then 5 µl of
each PCR reaction were analyzed by 1% agarose gel electrophoresis. For
nested RT-PCR of AFP or vAFP in various human tissues, one-fourth of
the cDNA synthesized from 10 µg of total RNAs
(CLONTECH) were used for the first PCR.
One-hundredth of the volume of the first PCR product was applied for
nested PCR using an internal primer set. The PCR consisted of 1 cycle
of 3 min at 95 °C; 30 cycles of 1.7 min at 95 °C, 2 min at
62 °C, 1.5 min at 72 °C followed by a 4.5 min extension at
72 °C. Then, 5 µl of each sample were analyzed in 2% agarose
gels. For RT-PCR of sorted cells from human umbilical cord blood cells,
total RNA was isolated with RNeasy kit (Qiagen). cDNAs synthesized
from total RNAs of sorted cells were normalized by the cell number.
Nested PCR for vAFP was performed with cDNA equivalent to 48,000 cells. Single step RT-PCR for -actin or CD34 was done with cDNA
equivalent to that of 1000 cells. For analysis of the genomic sequence
of exon A, genomic DNAs were isolated from HepG2, K562, and MRC5 with
QIAamp Tissue Kit (Qiagen). Amplified PCR products, using g-ex-AS and
g-ex-AA primers (Table I), were cloned
into pCRII-TOPO (Invitrogen), and the DNA sequences were determined by
the DNA sequencing core facility of the University of North Carolina at
Chapel Hill (Dr. Laura Livingston, director).
Identification of the 5'-End of Variant AFP Transcripts--
The
rapid amplification of cDNA ends (RACE) method (14) was performed
with modifications to identify the 5'-end of the vAFP transcripts.
Briefly, with terminal transferase (Roche Molecular Biochemicals), a
poly(dG) tail sequence was introduced into K562 cDNA derived from
10 µg of total RNA. One-tenth volume of the cDNA was amplified
for the first 5 cycles with 94 °C for 1 min, 45 °C for 1.5 min,
and 72 °C for 2.5 min, followed by 15 cycles with 94 °C for 1 min, 60 °C for 1.5 min, and 72 °C for 2.5 min using SN-poly(C)
primer and ex-2A, ex-3A, or ex-4A. PCR products purified with QIAquick
PCR purification kit (Qiagen) were reamplified with SN primer and an
internal AFP primer (ex-1A, ex-2A, or ex-3A) at 94 °C for 1 min,
62 °C for 1.5 min, and 72 °C for 2.5 min for 30 cycles. The final
PCR products were cloned into pCRII-TOPO and sequenced.
Umbilical Cord Blood (UCB) Cell Preparation and
Fluorescence-activated Cell Sorting--
Human UCB was obtained from
the Carolina Cord Blood Bank following institutional review
board-approved informed consent. UCB was processed as described (27).
Unfractionated nucleated UCB cells were prepared by deleting red blood
cells with the use of Hespan (DuPont Pharma, Wilmington, CE) and
hemolysis at 37 °C in 0.17 M NH4Cl, 20 mM Tris-HCl, pH 7.2, and 200 µM EDTA.
Lineage-committed cells were removed from the unfractionated cells
using the StemSep enrichment system (progenitor mixture, StemCell
Technologies Inc, Vancouver, British Columbia). The recovered cells
were termed Lin UCB cells. Cells were purified using a
FACStar Plus cell sorter (Becton Dickinson Immunocytometry Systems
(BDIS), San Jose, CA). For cell sorting, the Lin UCB cells
were stained with a mixture of three phycoerythrin (PE)
conjugated CD34-specific antibodies (clones Qbend10, Immu133 and
Immu409, Beckman Coulter, Miami, FL). For all cell sorting, (7-aminoactinomycin D (Molecular Probes; 7AAD) was used to exclude dying cells. This was added to a final concentration of 10 µg/ml during the antibody incubations. In some instances, the expression of
CD38 was also monitored (clone HB7, BDIS).
 |
RESULTS |
Variant AFP mRNA Expressed in K562, a Human Erythroleukemia
Cell Line--
The human AFP gene consists of 15 exons
(Fig. 1A). The coding sequence
is from exon 1 to exon 14 (20). To investigate the expression of
possible variant forms of AFP mRNA in hematopoietic cells, two
different portions of the AFP cDNA sequence were selected as target
sequences of RT-PCR. The primer combination of ex-1S and ex-3A was used
to amplify exon 1 containing the initiation methionine to exon 3, and
the combination of ex-12S and ex-14A was used to amplify exon 12 to
exon 14 containing the termination codon (Fig. 1B). The
results of the PCR are shown in Fig.
2A. Both combinations of the
primers resulted in intense amplification bands in the cDNA from
HepG2, a hepatocellular carcinoma cell line (lanes 1 and
2). By contrast, cDNA from the erythroleukemia cell
line, K562, showed an amplification band only for the C-terminal portion, identified by the ex-12S and ex-14A (lane 5)
whereas there was no band by PCR of the primer combination of ex-1S and ex-3A (lane 4). This result suggests that K562 expresses a
short form of authentic AFP transcript without the N terminus. In fact, the result of the PCR for the whole coding region of AFP using ex-1S
and ex-14A primers showed that the single band of 1.8 kb (lane
3) was amplified from the HepG2 cDNA, whereas there was no
detectable band in K562 (lane 6).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic representation of the human
AFP gene, AFP transcript, and position of primers used
for RT-PCR. A, human AFP gene consists of 15 exons and 14 introns and spans ~20,000 base pairs. The initiation
methionine codon (ATG) and the termination codon (TAA) of the AFP
transcript are indicated in exon 1 and exon 14, respectively.
B, approximate position of sense primers and antisense
primers are shown. The nucleotide sequences of primers were described
in Table I.
|
|

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 2.
Expression of AFP mRNAs in K562 and HepG2
was analyzed by RT-PCR. A, primer combination of ex-1S
and ex-3A (lanes 1, 4, and 7), ex-12S
and ex-14A (lanes 2, 5, and 8), or
ex-1S and ex-14S (lanes 3, 6, and 9) was used to
amplify exon 1 to exon 3, exon 12 to exon 14, or exon 1 to exon 14 of
AFP cDNA, respectively. B, series of 5'-primers from
exon 1 to exon 6 (ex-1S to ex-6S) and ex-14A as the 3'-primer were used
to detect AFP transcripts. Lanes 1, 3,
5, 7, 9, and 11 for K562.
Lanes 2, 4, 6, 8, 10, and 12 for HepG2. The amount of HepG2 cDNA was
one-hundredth of that from K562. The right panel in
A and B shows expression of -actin.
A, lane 10, HepG2; lane 11, K562; and
lane 12, control. B, lane 13, HepG2;
lane 14, K562; and lane 15, control. Open
triangle indicates 1 kbp.
|
|
The AFP genes in rats, mice, and humans are organized
similarly into 15 coding exons interrupted by 14 introns (20-22).
Although there has been no report about any variant form of the AFP
mRNA in humans, several short forms of the AFP transcript have been characterized in rats (23, 24). The rat vAFP lacks the first six or
seven exons, but shares common 3'-sequences containing the seventh or
eighth exon to the fifteenth exon, respectively (23). Detailed analysis
of one variant form of rat showed that the rat vAFP used an additional
exon, designated as exon V that is located in the seventh intron of the
rat gene, as the first exon of the variant form. However, it turned out
that human vAFP transcripts in K562 had different structures from the
rat vAFP because RT-PCR of the primer combination exon 7 and ex-14A
could detect the variant transcripts (data not show). Therefore, a
series of 5'-primers from exon 2 to exon 6 were constructed (Fig.
1B) to see the difference between authentic and variant
forms of AFP transcripts in K562. With each of these, ex-14A primer was
used as a 3'-primer. The results of the RT-PCR showed, intriguingly, that human variant AFP transcripts in hematopoietic cells share the
entire coding exons, except for exon 1, in the authentic form that is
expressed in HepG2 (Fig. 2B). Recently, it has been reported that an AFP isoform using a new exon located in intron 1 is expressed preferentially in the yolk sac and fetal liver in the mouse (25). However, no detectable amplified band in the PCR using an intron 1-specific 5'-primer (data not shown) suggested that the human vAFP
transcripts in hematopoietic cells are novel isoforms of AFP.
Molecular Cloning of Variant AFP cDNA from K562--
To
determine the sequences of the 5'-end of the vAFP transcript in K562,
the RACE method was applied as described under "Experimental Procedures." As a result, two types of variant transcripts were identified. The sequences are shown in Fig. 3A. Comparing
the sequences of the variant transcripts to the GenBankTM
data base, two regions of genomic sequence of the human AFP
gene were identified. One type (type A) of the variant forms used an additional exon, designated as exon A, located about 5 kb upstream from
exon 1 (Fig. 3B). The other
type (type AB) used exon A in conjunction with another exon, designated
as exon B, located about 1.6 kb upstream from exon 1 (Fig.
3B). Among 19 clones analyzed in these experiments, 15 clones were type A; 3 clones were type AB; and one clone was the germ
line transcript of intron 1. Although the genomic sequences containing
exon A were reported originally from Watanabe et al. (26),
some nucleotides in the exon A of K562 differed from the genomic
sequence (Fig. 3A, underline). First, to
determine whether this difference arose from artifacts associated with
the anchored PCR technique, the genomic sequence of exon A in K562
cells was compared with the cloned cDNA sequence. This showed that
the cDNA and genomic DNA of K562 cells were identical (data not
shown). Next, to determine whether the genomic sequence of exon A of
K562 is specific for the cell line, the genomic sequence of HepG2 and
normal human fibroblasts, MRC5, was compared with that of K562. The
results indicated no difference in the genomic sequence from all three
sources, K562, HepG2, and MRC5 (data not shown). In addition, the
genomic DNA sequence on the AFP locus from the data base of the human
genome project (GenBankTM; accession no. AP002825)
corresponded with the sequences of K562. These results suggest that the
DNA sequence of exon A cloned from K562 does not include artifacts from
the PCR cloning.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
Molecular structure and expression of
vAFP. A, DNA sequences of two variant forms of AFP
transcripts isolated from K562 cDNA. B, schematic
illustration of genomic structure of variant AFP. Open boxes
and horizontal lines indicate exons and introns,
respectively. Their lengths in nucleotides are indicated by numbers
above or below these elements. One type of the
variant forms used one additional exon (exon A) located
~5-kb upstream from exon 1. The other type used exon A and another
exon (exon B) located ~1.6 kb from exon 1. Genomic organization of
the variant forms was deduced from genomic sequence of the
AFP gene. C, selective expression of variant AFP
transcripts in K562. RT-PCR of primer combination of exon A primer
(ex-AS) and ex-14A primer were performed with cDNA from K562
(lane 1) and HepG2 (lane 2). K562, but not HepG2,
expressed variant forms of AFP transcripts. The strong signal of HepG2
by RT-PCR using ex-2S and ex-14A indicates that HepG2 expresses the
authentic form only. Equal amounts of cDNA were used for the
reaction. Lane 3, control reaction.
|
|
Selective Expression of Variant Transcripts in K562--
The
expression pattern of the variant and authentic transcripts of AFP was
studied in K562 and HepG2. A sense primer of exon A for RT-PCR was
designed. The combination of the exon A primer, ex-AS, and exon 14 primer, ex-14A, successfully detected the transcripts in K562, but not
HepG2 (Fig. 3C). The amplified products from K562 were
cloned and sequenced. As expected, the two types of variant AFP
transcripts either using both exons A and B or exon A alone were
followed by exon 2 to exon 14. The number of clones with a type A
sequence was 7 of 12, while that of type AB clone was 5 of 12 (data not
shown). This suggests that the two types of vAFP are expressed equally
in K562. The far stronger signal of HepG2 by RT-PCR using ex-2S and
ex-14A indicated that HepG2 expressed the authentic form only. This
result demonstrated clearly that the expression pattern of variant and
authentic forms of AFP rigorously discriminates between K562 and HepG2 cells.
Expression of Variant Forms of AFP in Normal Human Tissues--
We
next examined whether the variant transcripts of AFP are expressed in
normal cells. Since we anticipated the expression in normal cells would
be at very low levels, a nested (two step) RT-PCR was performed. The
first PCR was performed with primers, ex-A1S and ex-14A, to amplify the
whole coding sequence of variant forms. Subsequently, nested PCR was
performed by an internal primer combination, ex-A2S and ex-3A, which
can distinguish between the presence of type A and type AB by the
molecular size (Fig. 4A). The
PCR results indicate that the tissue distribution of the vAFP transcripts is fairly restricted. Only primary hematopoietic organs, bone marrow (lane 1) and thymus (lane 2), and
brain (lane 7) expressed the transcripts. Other tissues,
including liver, lung, trachea, kidney, stomach, small intestine,
colon, heart, and spleen, did not have cells expressing vAFP. These
results strongly suggest that hematopoietic progenitors, but not mature
blood cells, express vAFP, because the spleen is a secondary
hematopoietic organ in which hemato-lymphopoiesis does not take place
under normal physiological conditions. In addition, cDNA from
peripheral blood cells (CLONTECH) never showed the
expression of vAFP (data not shown). On the other hand, authentic AFP
was detected in brain, kidney, small intestine, and thymus, but not in
bone marrow. No expression in normal human fetal fibroblasts
(lane 13) or small intestine (lane 4) suggests that the vAFP expression is not associated simply with cell
proliferation.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 4.
RT-PCR analyses of variant AFP transcripts in
normal human tissues. A, nested PCR strategy. First PCR
(PCR-1) of primer combination of ex-A1S/ex-14A and second PCR (PCR-2)
of that of ex-A2/ex-3A are illustrated. The amplified DNA fragments of
two AFP variant forms were distinguishable in agarose electrophoresis.
B, expression of variant AFP mRNAs was analyzed in
cDNAs from various human tissues. Lane 1, bone marrow;
lane 2, thymus; lane 3, spleen; lane
4, small intestine; lane 5, colon; lane 6,
stomach; lane 7, brain; lane 8, heart; lane
9, kidney; lane 10, liver; lane 11, lung;
lane 12, trachea; lane 13, MRC5; lane
14, K562; and lane 15, no template. Nested RT-PCR of
the authentic AFP transcript was performed with the same human tissues
cDNAs. Primer combination of ex-1capS/ex-14A for first PCR and that
of ex-1S/ex-3A for second PCR were used. The result from single step
RT-PCR of -actin is shown at the bottom. Open
and closed triangles indicate 500 or 1000 bp of the ladder
marker, respectively.
|
|
Variant Transcripts of AFP Expressed in Hematopoietic
Progenitors--
The RT-PCR of tissue RNAs cannot define which cells
express the variant forms of AFP transcripts. Bone marrow and thymus
consist of a very heterogeneous cell population. Therefore, we studied purified hematopoietic progenitors from UCB by flow cytometric sorting
to learn whether or not they express vAFP. Unfractionated nucleated
cells in UCB contain only small numbers of CD34+ cells
(Fig. 5A) in which
hematopoietic progenitors are highly enriched (27). The
CD34+ UCB cells could be enriched after removing
Lin-positive cells (Fig. 5A). Both live (7AAD ),
unfractionated cells and CD34+Lin cells were
isolated by flow cytometric sorting, and the RNAs extracted were
subjected to nested PCR for vAFP. A total of four different cord bloods
were tested. As shown in Fig. 5B, the expression of vAFP
transcripts was detected in CD34+Lin cells,
enriched hematopoietic progenitors (lanes 2, 4, 6, and 8; 4 of 4), but not in unfractionated cord blood cells
(lanes 1, 3, and 5; 3 of 4). Cloning
and DNA sequencing experiments showed that the amplified bands
corresponded to cDNA sequences of type A and type AB from K562
cells (data not shown). CD34 expression in the sorted
CD34+Lin cells was confirmed by RT-PCR (Fig.
5B).

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of variant AFP transcripts in
normal human hematopoietic prgenitors. A,
representative dot plot of flow cytometry for CD34 and CD38 expression
in UCB cells after ficoll centrifugation are shown at the
left. CD34+ cell population was 2.3% on the
average. CD34+ cell population was enriched after removing
Lin+ cells. Live CD34 cell fraction (inside of open
box) was sorted for RT-PCR analysis. B, RT-PCR analyses
of variant AFP transcripts of sorted UCB were performed as described in
the legend to Fig 3. Roman numerals indicate individual UCB
samples. Lanes 1, 3, 5, and
7, unfractionated UCB cells; lanes 2,
4, 6, and 8,
CD34+Lin UCB cells; lane 9, K562;
lane 10, control reaction.
|
|
 |
DISCUSSION |
The present study identified two variant forms of AFP expressed
preferentially in hematopoietic progenitors, but not in mature blood
cells or in hepatic cells. These results suggest that the AFP gene
locus of chromatin in hematopoietic progenitors is open and accessible
to transcription factors for the mRNA expression. In other words,
chromatin-related repression of authentic AFP, which is a mechanism
that will block inappropriate expression of authentic AFP in
non-hepatic cells (28), is incomplete in hematopoietic progenitors and
allows vAFP to be transcribed. In the case of K562, strictly speaking,
very small amounts of authentic AFP transcripts could be detected when
cycles of RT-PCR were increased (Fig. 4B, lane
14). This indicates that K562 express vAFP at a much higher level
than authentic AFP. Conversely, vAFP could be detected in HepG2 by
increasing cycles of RT-PCR (data not shown). Therefore, our data
derived from the cell lines suggest that three types of patterns are
present with respect to the authentic and variant transcripts of AFP.
Hepatic cells (HepG2) express authentic AFP dominantly, while
hematopoietic cells (K562) express vAFP dominantly. Fibroblasts (MRC5)
express neither authentic AFP nor vAFP. This prompts us to ask two
questions with respect to AFP expression. 1) What is the mechanism of
the opening of the AFP locus in the chromatin, giving rise to whichever
of the transcripts is expressed? 2) What is the transcriptional
machinery associated with the different transcripts?
The mouse has proved an excellent model system for studying
tissue-specific and developmentally regulated transcriptional control
of authentic AFP in vivo as well as in vitro
(14-16). Extensive studies have established that the transcriptional
control of the AFP gene is mediated by five cis-acting
regulatory domains, including the AFP promoter, three
distinct enhancer elements, and one repressor region located between
the AFP promoter and the upstream enhancers (reviewed in
Ref. 29). There are a number of transcription factors binding to the
promotor region to control the expression of the authentic AFP form
(reviewed in Ref. 29). It has been proposed that GATA factors,
especially GATA4, could be a master gene for endodermal differentiation
(30) and for the expression of fetoprotein transcription factor, which
activates AFP expression in early liver development (31). On the other
hand, other GATA factors are key regulators for hematopoiesis (32).
Interestingly, several possible GATA family binding sites were
identified in the exon A genomic sequence as well as other
transcription factor binding sites associated with hematopoiesis such
as AML-1 (33) and MZF-1 (34). Because exon A was identified as only one
5'-end of two variant forms by our RACE method in all independent
clones, exon A is possibly the first exon of vAFP in K562. Thus, it is
noteworthy to see whether these transcription factors expressed in
hematopoietic progenitors are involved in the transcription of vAFP.
However, the transcriptional start site of the variant forms of AFP in hematopoietic cells remains to be determined.
Although extensive research has been performed to elucidate
AFP gene regulation in various species (15, 35), there has been no report about human variant AFP transcripts nor identification of exon A and exon B 5'-upstream of exon 1 in any species. Variant AFP
transcripts identified in rodents were expressed preferentially in
hepatic or yolk sac cells (24, 25). These suggest that the vAFP
transcripts in the human hematopoietic cells are different from ones
identified in rat or in mouse not only in their molecular structures,
but also in their expression pattern. Interestingly, all variant forms
of AFP reported in the previous studies and this study use unique first
exons. Because the different usage of the first exon suggests that the
vAFP expression is dependent on a unique promotor (24, 25), further
studies are required to elucidate the hematopoietic cell-specific
promotor of vAFP.
At present, apart from the hematopoietic organs, the brain is the only
tissue where vAFP expression is observed. It has been shown that
cultured neurospheres, which are considered as neural stem cells,
isolated from the anterior portion of the lateral wall of the lateral
ventricles in adult mice were able to differentiate to endodermal cells
(36). Therefore, it is important to determine the identity of
vAFP+ cells in the brain and isolate them from brain tissue
in order to ask whether they have a capability to form neurospheres
in vitro. The expression of vAFP in non-endodermal cells may
represent a unique immature state, which has the developmental
potential of endodermal cells.
The function of the vAFP is unclear because the amount of mRNA was
extremely low, and no protein products were ever found in assays using
immunohistochemistry with anti-AFP antibodies on hematopoietic
progenitors.2 In addition,
there is no long open reading frame starts in exon A or B to connect
with exon 2 of authentic AFP if only ATG is considered as an initiation
codon. In that case, a possible initiation codon at exon 3 would be
used for the translation so that the translated product from vAFP
transcripts would be a truncated form. However, because there is TTG
and CTG in exon B to connect the open reading frame of exon 2, it might
be possible for one of them to work as an alternative initiation codon
(37, 38). In any event, further studies are required to elucidate the
possible functions of vAFP transcripts.
As a final point, this study raises a warning about the use of
RT-PCR techniques for the detection of AFP mRNA. AFP is used commonly as a molecular marker for endodermal differentiation (17-19)
or certain carcinomas such as hepatomas or germ cell tumors (15, 35).
Various RT-PCR techniques have been developed for the detection of
circulating carcinoma cells in peripheral blood (39). Nevertheless,
none of them, to the best of our knowledge, used exon 1-specific
primers to detect the authentic form of AFP. Thus, the use of not only
the exon 1-specific primer but the exon A-specific primer for RT-PCR to
analyze AFP mRNA expression will be necessary to consider which
types of transcripts are expressed in the cells examined.
In conclusion, this is the first study in which variant forms of an
endodermal marker, AFP, have been found, with a selective pattern of
expression in human hematopoietic progenitors. Our results suggest that
the expression of vAFP transcripts may reflect the ability of
progenitors for hematopoietic cells to differentiate to endodermal
cells and provides a unique opportunity for studying the mechanism.
 |
ACKNOWLEDGEMENTS |
We thank N. Moss for critical
evaluation of the manuscript, M. Cook for operating the cell sorter,
and C. Lodestro for laboratory management. We also thank members of the
laboratory for helpful discussion and encouragement.
 |
FOOTNOTES |
*
This work was supported by Grant RO1-DK52851 from the
National Institutes of Health and grants from Incara Cell Technologies (formerly Renaissance Cell Technologies), Research Triangle Park, NC.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF484525 and AF484526.
§
To whom correspondence may be addressed: Dept. of Animal Biology,
School of Veterinary Medicine, University of Pennsylvania, 3850 Baltimore Ave., Philadelphia, PA 19104-6009. Tel.: 215-898-8805; Fax:
215-898-0667; E-mail: kubota@vet.upenn.edu.
To whom correspondence may be addressed: Glaxo Bldg., Campus
Box 7038, University of North Carolina at Chapel Hill, School of
Medicine, Chapel Hill, NC 27599-7038. Tel.: 919-966-0346; Fax: 919-966-6112; E-mail: stemcell@med.unc.edu.
Published, JBC Papers in Press, May 10, 2002, DOI 10.1074/jbc.M202117200
2
N. Moss and H. Kubota, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
AFP, -fetoprotein;
vAFP, variant -fetoprotein;
RACE, rapid
amplification of cDNA ends;
UCB, umbilical cord blood;
MEM, minimal
essential medium;
DMEM, Dulbecco's MEM;
RT-PCR, reverse
transcriptase-PCR;
PE, phycoerythrin;
7AAD, 7-aminoactinomycin D.
 |
REFERENCES |
| 1.
|
Fuchs, E.,
and Segre, J. A.
(2000)
Cell
100,
143-155[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Xu, A. S. L.,
Luntz, T. L.,
Macdonald, J. M.,
Kubota, H.,
Hsu, E.,
London, R. E.,
and Reid, L. M.
(2000)
in
Principles of Tissue Engineering
(Lanza, R. P.
, Langer, R.
, and Chick, W. L., eds)
, pp. 559-598, Academic Press, San Diego, CA
|
| 3.
|
Lagasse, E.,
Shizuru, J. A.,
Uchida, N.,
Tsukamoto, A.,
and Weissman, I. L.
(2001)
Immunity
14,
425-436[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Phillips, R. L.,
Ernst, R. E.,
Brunk, B.,
Ivanova, N.,
Mahan, M. A.,
Deanehan, J. K.,
Moore, K. A.,
Overton, G. C.,
and Lemischka, I. R.
(2000)
Science
288,
1635-1640[Abstract/Free Full Text]
|
| 5.
|
Terskikh, A. V.,
Easterday, M. C., Li, L.,
Hood, L.,
Kornblum, H. I.,
Geschwind, D. H.,
and Weissman, I. L.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
7934-7939[Abstract/Free Full Text]
|
| 6.
|
Bjornson, C. R.,
Rietze, R. L.,
Reynolds, B. A.,
Magli, M. C.,
and Vescovi, A. L.
(1999)
Science
283,
534-537[Abstract/Free Full Text]
|
| 7.
|
Krause, D. S.,
Theise, N. D.,
Collector, M. I.,
Henegariu, O.,
Hwang, S.,
Gardner, R.,
Neutzel, S.,
and Sharkis, S. J.
(2001)
Cell
105,
369-377[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Lagasse, E.,
Connors, H., Al-,
Dhalimy, M.,
Reitsma, M.,
Dohse, M.,
Osborne, L.,
Wang, X.,
Finegold, M.,
Weissman, I. L.,
and Grompe, M.
(2000)
Nat. Med.
6,
1229-1234[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Morrison, S. J.
(2001)
Curr. Biol.
11,
R7-9[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Terada, N.,
Hamazaki, T.,
Oka, M.,
Hoki, M.,
Mastalerz, D. M.,
Nakano, Y.,
Meyer, E. M.,
Morel, L.,
Petersen, B. E.,
and Scott, E. W.
(2002)
Nature
416,
542-545[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Ying, Q. L.,
Nichols, J.,
Evans, E. P.,
and Smith, A. G.
(2002)
Nature
416,
545-548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Kubota, H.,
and Reid, L. M.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
12132-12137[Abstract/Free Full Text]
|
| 13.
|
Zaret, K.
(1998)
Curr. Opin. Genes Dev.
8,
526-531[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Tilghman, S. M.
(1985)
Oxf. Surv. Eukaryotic Genes
2,
160-206[Medline]
[Order article via Infotrieve]
|
| 15.
|
Chen, H.,
Egan, J. O.,
and Chiu, J. F.
(1997)
Crit. Rev. Eukaryotic Gene Expression
7,
11-41[Medline]
[Order article via Infotrieve]
|
| 16.
|
Hammer, R. E.,
Krumlauf, R.,
Camper, S. A.,
Brinster, R. L.,
and Tilghman, S. M.
(1987)
Science
235,
53-58[Abstract/Free Full Text]
|
| 17.
|
Thomson, J. A.,
Itskovitz-Eldor, J.,
Shapiro, S. S.,
Waknitz, M. A.,
Swiergiel, J. J.,
Marshall, V. S.,
and Jones, J. M.
(1998)
Science
282,
1145-1147[Abstract/Free Full Text]
|
| 18.
|
Schuldiner, M.,
Yanuka, O.,
Itskovitz-Eldor, J.,
Melton, D. A.,
and Benvenisty, N.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
11307-11312[Abstract/Free Full Text]
|
| 19.
|
Shamblott, M. J.,
Axelman, J.,
Littlefield, J. W.,
Blumenthal, P. D.,
Huggins, G. R.,
Cui, Y.,
Cheng, L.,
and Gearhart, J. D.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
113-118[Abstract/Free Full Text]
|
| 20.
|
Gibbs, P. E.,
Zielinski, R.,
Boyd, C.,
and Dugaiczyk, A.
(1987)
Biochemistry
26,
1332-1343[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Eiferman, F. A.,
Young, P. R.,
Scott, R. W.,
and Tilghman, S. M.
(1981)
Nature
294,
713-718[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Nahon, J. L.,
Danan, J. L.,
Poiret, M.,
Tratner, I.,
Jose-Estanyol, M.,
and Sala-Trepat, J. M.
(1987)
J. Biol. Chem.
262,
12479-12487[Abstract/Free Full Text]
|
| 23.
|
Lemire, J. M.,
and Fausto, N.
(1991)
Cancer Res.
51,
4656-4664[Abstract/Free Full Text]
|
| 24.
|
Watanabe, T.,
Jimenez-Molina, J. L.,
and Chou, J. Y.
(1992)
Biochem. Biophys. Res. Commun.
185,
648-656[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Scohy, S.,
Gabant, P.,
Szpirer, C.,
and Szpirer, J.
(2000)
Nucleic Acids Res.
28,
3743-3751[Abstract/Free Full Text]
|
| 26.
|
Watanabe, K.,
Saito, A.,
and Tamaoki, T.
(1987)
J. Biol. Chem.
262,
4812-4818[Abstract/Free Full Text]
|
| 27.
|
Storms, R. W.,
Goodell, M. A.,
Fisher, A.,
Mulligan, R. C.,
and Smith, C.
(2000)
Blood
96,
2125-2133[Abstract/Free Full Text]
|
| 28.
|
Crowe, A. J.,
Sang, L., Li, K. K.,
Lee, K. C.,
Spear, B. T.,
and Barton, M. C.
(1999)
J. Biol. Chem.
274,
25113-25120[Abstract/Free Full Text]
|
| 29.
|
Spear, B. T.
(1999)
Semin. Cancer Biol.
9,
109-116[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Zaret, K.
(1999)
Dev. Biol.
209,
1-10[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Pare, J. F.,
Roy, S.,
Galarneau, L.,
and Belanger, L.
(2001)
J. Biol. Chem.
276,
13136-13144[Abstract/Free Full Text]
|
| 32.
|
Tsai, F. Y.,
Keller, G.,
Kuo, F. C.,
Weiss, M.,
Chen, J.,
Rosenblatt, M.,
Alt, F. W.,
and Orkin, S. H.
(1994)
Nature
371,
221-226[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Okuda, T.,
van Deursen, J.,
Hiebert, S. W.,
Grosveld, G.,
and Downing, J. R.
(1996)
Cell
84,
321-330[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Morris, J. F.,
Rauscher, F. J., 3rd,
Davis, B.,
Klemsz, M., Xu, D.,
Tenen, D.,
and Hromas, R.
(1995)
Blood
86,
3640-3647[Abstract/Free Full Text]
|
| 35.
|
Lazarevich, N. L.
(2000)
Biochemistry (Mosc.)
65,
117-133[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Clarke, D. L.,
Johansson, C. B.,
Wilbertz, J.,
Veress, B.,
Nilsson, E.,
Karlstrom, H.,
Lendahl, U.,
and Frisen, J.
(2000)
Science
288,
1660-1663[Abstract/Free Full Text]
|
| 37.
|
Hann, S. R.,
King, M. W.,
Bentley, D. L.,
Anderson, C. W.,
and Eisenman, R. N.
(1988)
Cell
52,
185-195[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Prats, H.,
Kaghad, M.,
Prats, A. C.,
Klagsbrun, M.,
Lelias, J. M.,
Liauzun, P.,
Chalon, P.,
Tauber, J. P.,
Amalric, F.,
Smith, J. A.,
et al..
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1836-1840[Abstract/Free Full Text]
|
| 39.
|
Paterlini-Brechot, P.,
Vona, G.,
and Brechot, C.
(2000)
Semin. Cancer Biol.
10,
241-249[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. J. Mizejewski
Physiology of Alpha-Fetoprotein as a Biomarker for Perinatal Distress: Relevance to Adverse Pregnancy Outcome
Experimental Biology and Medicine,
September 1, 2007;
232(8):
993 - 1004.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kubota, H.-l. Yao, and L. M. Reid
Identification and Characterization of Vitamin A-Storing Cells in Fetal Liver: Implications for Functional Importance of Hepatic Stellate Cells in Liver Development and Hematopoiesis
Stem Cells,
September 1, 2007;
25(9):
2339 - 2349.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Schmelzer, L. Zhang, A. Bruce, E. Wauthier, J. Ludlow, H.-l. Yao, N. Moss, A. Melhem, R. McClelland, W. Turner, et al.
Human hepatic stem cells from fetal and postnatal donors
J. Exp. Med.,
August 6, 2007;
204(8):
1973 - 1987.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Schmelzer, E. Wauthier, and L. M. Reid
The Phenotypes of Pluripotent Human Hepatic Progenitors
Stem Cells,
August 1, 2006;
24(8):
1852 - 1858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-C. Chien, B. L. Yen, F.-K. Lee, T.-H. Lai, Y.-C. Chen, S.-H. Chan, and H.-I Huang
In Vitro Differentiation of Human Placenta-Derived Multipotent Cells into Hepatocyte-Like Cells
Stem Cells,
July 1, 2006;
24(7):
1759 - 1768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Fukasaw, H. Iwamoto, S. Hirata, T. Shoda, S. Yokota, S. Nishi, and K. Hoshi
Novel Human Alpha-Fetoprotein mRNA Isoform Lacking Exon 1 Identified in Ovarian Yolk Sac Tumor
Reproductive Sciences,
September 1, 2005;
12(6):
456 - 462.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Sharma, T. Cantz, R. Richter, K. Eckert, R. Henschler, L. Wilkens, A. Jochheim-Richter, L. Arseniev, and M. Ott
Human Cord Blood Stem Cells Generate Human Cytokeratin 18-Negative Hepatocyte-Like Cells in Injured Mouse Liver
Am. J. Pathol.,
August 1, 2005;
167(2):
555 - 564.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Mizejewski
Biological Roles of Alpha-Fetoprotein During Pregnancy and Perinatal Development
Experimental Biology and Medicine,
June 1, 2004;
229(6):
439 - 463.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M R Alison, R Poulsom, W R Otto, P Vig, M Brittan, N C Direkze, M Lovell, T C Fang, S L Preston, and N A Wright
Recipes for adult stem cell plasticity: fusion cuisine or readymade?
J. Clin. Pathol.,
February 1, 2004;
57(2):
113 - 120.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|